EKSO BIONICS HOLDINGS, INC.: Changed fiscal year end from December 31 to May 31.
“In connection with the Business Combination, as of the Closing Date, the Company changed its fiscal year end from December 31 to May 31.”
EKSO BIONICS HOLDINGS, INC. — fact timeline
Source-grounded facts extracted from EKSO BIONICS HOLDINGS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
EKSO BIONICS HOLDINGS, INC.: Second Amended and Restated Bylaws adopted effective upon Closing on May 5, 2026 (effective 2026-05-05).
“Upon Closing and effective upon Closing, the Company adopted the Second Amended and Restated Bylaws (the “A&R Bylaws” and, together with the A&R Articles, the “Amended Charter Documents”).”
EKSO BIONICS HOLDINGS, INC.: Second Amended and Restated Articles of Incorporation filed with Nevada Secretary of State, effective May 5, 2026, including name change to ChronoScale Corporation, increase in authorized common shares from 141,428,571 to 290,000,000, and other changes (effective 2026-05-05).
“on May 1, 2026, the Company filed the Second Amended and Restated Articles of Incorporation (the “A&R Articles”) with the Secretary of State of the State of Nevada with a delayed effective date and time of 3:00 a.m. (Eastern Time) on May 5, 2026.”
EKSO BIONICS HOLDINGS, INC. underwent a change of control involving Applied Digital Corporation (closed 2026-05-05).
“On May 5, 2026 (the “Closing Date”), Ekso Bionics Holdings, Inc., a Nevada corporation (“Ekso” or the “Company”), consummated the previously announced business combination transaction (the “Business Combination”) contemplated by that certain Contribution and Exchange Agreement”
Richard Nottenburg was appointed as Director at EKSO BIONICS HOLDINGS, INC..
“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”
Douglas Miller was appointed as Director at EKSO BIONICS HOLDINGS, INC..
“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”
Scott G. Davis was appointed as Director at EKSO BIONICS HOLDINGS, INC..
“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”
William M. Clancy was appointed as Director at EKSO BIONICS HOLDINGS, INC..
“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”
Ying Cenly Chen was appointed as Director at EKSO BIONICS HOLDINGS, INC..
“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”
Ella Benson was appointed as Director at EKSO BIONICS HOLDINGS, INC..
“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”
Wes Cummins was appointed as Chairman of the Board at EKSO BIONICS HOLDINGS, INC..
“the Board was reconstituted as follows: Wes Cummins (Chairman), Ella Benson, Ying Cenly Chen, the Company's Chief Executive Officer, William M. Clancy, Scott G. Davis, Douglas Miller and Richard Nottenburg”
Deborah Lafer Scher resigned as Director at EKSO BIONICS HOLDINGS, INC..
“the following directors tendered their resignations from the Board and each committee of the Board on which each such director respectively served: Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher”
Charles Li resigned as Director at EKSO BIONICS HOLDINGS, INC..
“the following directors tendered their resignations from the Board and each committee of the Board on which each such director respectively served: Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher”
Corinna Lathan resigned as Director at EKSO BIONICS HOLDINGS, INC..
“the following directors tendered their resignations from the Board and each committee of the Board on which each such director respectively served: Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher”
Mary Ann Cloyd resigned as Director at EKSO BIONICS HOLDINGS, INC..
“the following directors tendered their resignations from the Board and each committee of the Board on which each such director respectively served: Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher”
EKSO BIONICS HOLDINGS, INC. engaged CBIZ CPAs P.C. as its auditor.
“ay 5, 2026, the audit committee of the Board approved (i) the termination of the engagement of WithumSmith+Brown, PC (“Withum”), the Company’s independent registered public accounting firm prior to the Business Combination, and (ii) the engagement of CBIZ”
EKSO BIONICS HOLDINGS, INC. dismissed WithumSmith+Brown, PC as its auditor.
“On May 5, 2026, the audit committee of the Board approved (i) the termination of the engagement of WithumSmith+Brown, PC”
EKSO BIONICS HOLDINGS, INC. entered into Securities Purchase Agreement with Applied Parent valued at gross proceeds of approximately $15.75 million (effective 2026-05-01).
“the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Applied Parent (the “APLD Parent PIPE Investment”), pursuant to which the Company agreed to sell and issue to Applied Parent 1,311,407 shares of Common Stock (the “Private Placement Shares”).”
EKSO BIONICS HOLDINGS, INC.: Second Restated Bylaws introduce new provisions effective upon Closing, including quorum requirements, written consent rules, board quorum, amendment provisions, and no cumulative voting (effective 2026-02-14).
“On February 14, 2026, the Board approved the Second Restated Articles, which will only become effective immediately prior to the Closing, subject to stockholder approval, and the Second Amended and Restated Bylaws (the “Second Restated Bylaws”), which will only become effective upon the Closing.”
EKSO BIONICS HOLDINGS, INC.: Board approved Second Restated Articles, effective upon Closing, increasing authorized common shares from 141,428,571 to 290,000,000 and making other changes (effective 2026-02-14).
“On February 14, 2026, the Board approved the Second Restated Articles, which will only become effective immediately prior to the Closing, subject to stockholder approval, and the Second Amended and Restated Bylaws (the “Second Restated Bylaws”), which will only become effective upon the Closing.”
EKSO BIONICS HOLDINGS, INC.: Amendment No. 1 to Bylaws removes prohibition on stockholder action by written consent and revises record date provision to clarify applicability to meetings only (effective 2026-02-14).
“On February 14, 2026, the Board adopted an amendment (“Amendment No. 1”) to the Company’s amended and restated by-laws (the “Bylaws”) to align certain provisions of the Bylaws with Nevada law by (i) removing the provision of the Bylaws prohibiting stockholder action by written consent, and (ii) revising the record date provision to clarify that such provision is only applicable to meetings of stockholders.”
EKSO BIONICS HOLDINGS, INC. entered into Contribution and Exchange Agreement with APLD Intermediate HoldCo LLC, APLD ChronoScale HoldCo LLC, and Applied Digital Cloud Corporation (effective 2026-02-15).
“On February 15, 2026, Ekso Bionics Holdings, Inc., a Nevada corporation (“Ekso” or the “Company”), entered into a Contribution and Exchange Agreement (the “Contribution and Exchange Agreement”) with APLD Intermediate HoldCo LLC, a Delaware limited liability company (“APLD Intermediate”), APLD ChronoScale HoldCo LLC, a Delaware limited liability company and a wholly owned subsidiary of APLD Intermediate (“Contributor”), each a wholly owned direct or indirect subsidiary of Applied Digital Corporation, a Nevada corporation (“APLD”), and Applied Digital Cloud Corporation, a Nevada corporation, which at the time of the Closing (as defined below), will be a wholly owned subsidiary of Contributor (“Cloud”)”
EKSO BIONICS HOLDINGS, INC.: Filed a Certificate of Designation for Series B Convertible Preferred Stock to the Restated Articles of Incorporation (effective 2026-01-22).
“In connection with the Private Placement, on January 22, 2026, the Company filed a Certificate of Designation of the Powers, Preferences and Relative, Participating, Option and Other Restrictions of the Series B Preferred Stock (the “Certificate of Designation”) to the Company’s Restated Articles of Incorporation with the Secretary of State of the State of Nevada.”
EKSO BIONICS HOLDINGS, INC. entered into Purchase Agreements with certain institutional and accredited investors valued at approximately $5.3 million (effective 2026-01-20).
“On January 20, 2026, Ekso Bionics Holdings, Inc. (the “Company”) entered into securities purchase agreements (collectively, the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Private Placement”), (i) an aggregate of 5,852 shares of the Company’s newly designated Series B Convertible Preferred Stock, with a par value $0.001 per share and stated value (the “Stated Value”) of $1,000 per share (the “Series B Preferred Stock”) convertible into an aggregate of 711,922 shares (the “Conversion Shares”) of common stock of the Company, par value $0.001 per share (the “Common Stock”) at a conversion price of $8.22 per share, subject to certain customary adjustments, and (ii) warrants (the “Warrants”) to purchase up to an aggregate of 355,960 shares of Common Stock at an exercise price of $8.22 per share of Common Stock.”
EKSO BIONICS HOLDINGS, INC. incurred term loan of $2.0 million with B. Riley Commercial Capital, LLC at 10.0% per annum maturing the earlier of the receipt of $2.4 million in net proceeds from the sale of the equity interests of the Company from new equity investors (a “Qualified Financin.
“On September 12, 2025, Ekso Bionics Holdings, Inc. (the “Company”) entered into a Secured Promissory Note and Security Agreement (the “Agreement”), by and among the Company, Ekso Bionics, Inc., a Delaware corporation and subsidiary of the Company (the “Subsidiary”), as guarantor, and B. Riley Commercial Capital, LLC, as lender (the “Lender”). The Agreement provides for a secured term loan in an aggregate principal amount of up to $2.0 million.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.